Johnson & Johnson (JNJ) was Reiterated by RBC Capital Mkts to “Outperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 122 from a previous price target of $114 . RBC Capital Mkts advised their investors in a research report released on Apr 15, 2016.
Many Wall Street Analysts have commented on Johnson & Johnson. Johnson & Johnson was Upgraded by Goldman to ” Neutral” on Mar 14, 2016.
On the company’s financial health, Johnson & Johnson reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jan 26, 2016. Analyst had a consensus of $1.42. The company had revenue of $17811.00 million for the quarter, compared to analysts expectations of $17856.07 million. The company’s revenue was down -2.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.27 EPS.
Johnson & Johnson closed down -0.13 points or -0.12% at $108.97 with 68,23,922 shares getting traded on Monday. Post opening the session at $109.15, the shares hit an intraday low of $108.65 and an intraday high of $109.62 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Feb 4, 2016, Peter Fasolo (VP, Global Human Resources) sold 151,385 shares at $104.11 per share price. According to the SEC, on Nov 24, 2015, Michael H Ullmann (VP, General Counsel) sold 17,650 shares at $102.47 per share price. On Nov 4, 2015, Dominic J Caruso (VP, Finance; CFO) sold 20,569 shares at $102.21 per share price, according to the Form-4 filing with the securities and exchange commission.
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.